WO2005034975A1 - 植物種子抽出組成物及びその製造方法 - Google Patents
植物種子抽出組成物及びその製造方法 Download PDFInfo
- Publication number
- WO2005034975A1 WO2005034975A1 PCT/JP2004/015087 JP2004015087W WO2005034975A1 WO 2005034975 A1 WO2005034975 A1 WO 2005034975A1 JP 2004015087 W JP2004015087 W JP 2004015087W WO 2005034975 A1 WO2005034975 A1 WO 2005034975A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plant seed
- composition
- extract
- safflower
- seed extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 103
- 239000000284 extract Substances 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 30
- 241000196324 Embryophyta Species 0.000 claims abstract description 88
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000003960 organic solvent Substances 0.000 claims abstract description 28
- 235000013305 food Nutrition 0.000 claims abstract description 26
- 238000005406 washing Methods 0.000 claims abstract description 22
- 229930182470 glycoside Natural products 0.000 claims abstract description 20
- 229940023866 safflower seed extract Drugs 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- 244000020518 Carthamus tinctorius Species 0.000 claims description 52
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 52
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 150000002338 glycosides Chemical class 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 108010021724 tonin Proteins 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical class C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 21
- WGHKJYWENWLOMY-CLTKARDFSA-N cis-Moschamine Natural products C1=C(O)C(OC)=CC(\C=C/C(=O)NCCC=2C3=CC(O)=CC=C3NC=2)=C1 WGHKJYWENWLOMY-CLTKARDFSA-N 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 15
- WGHKJYWENWLOMY-XVNBXDOJSA-N N-feruloylserotonin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)NCCC=2C3=CC(O)=CC=C3NC=2)=C1 WGHKJYWENWLOMY-XVNBXDOJSA-N 0.000 abstract description 14
- -1 p-coumaroylserotonin glycoside Chemical class 0.000 abstract description 13
- 238000001727 in vivo Methods 0.000 abstract description 7
- WLZPAFGVOWCVMG-FPYGCLRLSA-N N6-cis-p-Coumaroylserotonin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)NCCC1=CNC2=CC=C(O)C=C12 WLZPAFGVOWCVMG-FPYGCLRLSA-N 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 235000012054 meals Nutrition 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 206010003210 Arteriosclerosis Diseases 0.000 description 18
- 208000011775 arteriosclerosis disease Diseases 0.000 description 18
- 206010012735 Diarrhoea Diseases 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- LWYAMIUSVGPFKS-UHFFFAOYSA-N 2-Hydroxy-arctiin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(OC3C(C(O)C(O)C(CO)O3)O)=CC=2)(O)C(=O)OC1 LWYAMIUSVGPFKS-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 description 11
- 102000007330 LDL Lipoproteins Human genes 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000019779 Rapeseed Meal Nutrition 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000004456 rapeseed meal Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 240000002791 Brassica napus Species 0.000 description 5
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000489 anti-atherogenic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 101150037123 APOE gene Proteins 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000692 cap cell Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- RTANHMOFHGSZQO-UHFFFAOYSA-N 4-methoxy-2,4-dimethylpentanenitrile Chemical compound COC(C)(C)CC(C)C#N RTANHMOFHGSZQO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000206609 Porphyra Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 238000010165 Scheffé test Methods 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000008235 industrial water Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Plant seed extract composition Plant seed extract composition and method for producing the same
- the present invention provides a novel plant seed extract composition which can be used for prevention of arteriosclerosis, a food, a feed and a pharmaceutical composition containing the plant seed extract composition, and a production of the plant seed extract composition. About the method.
- safflower seeds are known to contain serotoyun derivatives which are known to have antioxidant and anti-inflammatory activities in vitro (Zhang et al., Chem. Pharm. Bull., 44: ⁇ 874-876). Kawasaki et al., J. Interferon Cytokine Res., 18: PP423-428, 1998). It is also known that safflower seeds contain a serotonin derivative which is a glycoside (Zhang et al., Chem. Pharm. Bull., 45: ⁇ 1910-14, 1997).
- An object of the present invention is to provide a novel plant seed extract composition containing a large amount of active ingredients having in vivo activity and reduced side effects, and a food, feed, or pharmaceutical composition containing the plant seed extract composition. And a method for producing the plant seed extract composition, the method being suitable for producing a food, feed, or pharmaceutical composition.
- Koyama et al Extracted organic solvent extracts of defatted plant seeds, especially safflower seeds and rapeseed seeds (extraction of aqueous extract of defatted seeds with hexane, followed by extraction with ethyl acetate).
- the present inventors have conducted further intensive studies in order to solve the above-mentioned problems, and as a result, by washing the defatted plant seeds with water and extracting it with an organic solvent from the resulting washed product, the content of the serotonin derivative was improved. For the first time, and found that a composition having a high content and a low content of 2-hydroxyarctiin was obtained, leading to the completion of the present invention. It was. Since the method of the present invention can be carried out using a production agent which can be generally used for producing a food, feed, or pharmaceutical composition, it is suitable for producing a food, feed, or pharmaceutical composition.
- the present invention includes the following items.
- a plant seed extract composition obtained by washing defatted plant seeds with water and extracting the resulting washed product with an organic solvent.
- composition according to (1) or (2), wherein the plant seed is a safflower seed.
- composition according to the above (4) which is obtained by washing defatted safflower seeds with water and extracting the resulting washed product with an organic solvent.
- a method for producing a plant seed extract composition comprising a step of washing a defatted plant seed with water and extracting the resulting washed product with an organic solvent.
- a method for producing a plant seed extract composition comprising a step of concentrating and drying an extract obtained by extraction.
- the plant seed extract composition of the present invention is a novel composition having a large content of a serotonin derivative as an active ingredient and a small content of 2-hydroxyarctiin which is a diarrhea-inducing compound. According to the method of the present invention, the above-described plant seed extract composition can be suitably produced.
- the method of the present invention is generally preferably used as a production agent in order to contribute to uses such as food and feed. Since it can be produced without using any ethyl acetate, it is suitable for the production of food and feed.
- FIG. 1 is a graph showing the effect of each sample on the oxidizability of LDL in Reference Example 1.
- Figure 2 shows that in Reference Example 2, the safflower meal extract composition and the rapeseed meal extract composition were expressed in the major arteries of apoE (-/-) mice [arteriosclerosis model mice] (five weeks of administration, 14 weeks of age).
- apoE apoE
- FIG. 2 is a schematic diagram in which the photograph is drawn to clarify the red-stained portion, and the red-stained portion is blacked out.
- FIG. 3 is a graph showing the lesion area of the aortic root of apoE knockout mouse (21 weeks old, os) at 15 weeks of each sample administration in Reference Example 3.
- SFM indicates safflower meal extract composition
- CS indicates p-coumaroyl serotonin
- FS indicates Hue / Leroy / reserotonin.
- the plant seed used in the present invention may be any plant seed, such as safflower, rapeseed, soybean, etc., and is preferably safflower seed.
- the plant seed may be a whole or a part of the plant seed, for example, a seed coat, endosperm, germ, etc., or a mixture thereof.
- a defatted plant seed that is, a defatted product (meal) is used as a raw material.
- the defatted plant seeds can be obtained by defatting the plant seeds by a method known per se.For example, after extracting the seeds by pressing or extracting by adding n-hexane or the like to the crushed seeds, The solid content can be obtained by extracting the solid content from the extraction system and drying the solid content.
- the degree of degreasing is usually 60% by weight or more, preferably 80% by weight or more.
- the present invention is characterized in that the defatted plant seeds as a raw material are washed with water before the organic solvent extraction described below.
- the water is not particularly limited, and for example, any of distilled water, tap water, industrial water, and mixed water thereof can be used.
- Water may contain other substances such as inorganic salts (eg, sodium chloride, potassium chloride, calcium chloride, etc.), acids (eg, hydrogen chloride, acetic acid, carbonic acid, carbon dioxide, hydrogen peroxide, phosphorus) as long as the effects of the present invention are obtained. Acids, etc.), and alkali metals (eg, sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, etc.).
- the pH at the time of washing is usually 2 to 9, and preferably 5 to 7.
- the amount of water used is generally 2 to 100 times the amount of the defatted plant seeds as the raw material (water capacity of the defatted plant seeds, hereinafter the same), preferably 10 to 40 times. Double the amount.
- the washing can be carried out by bringing the defatted plant seed, which is a raw material, into contact with water by a method known per se.
- a method in which a defatted plant seed is suspended in water and then filtered to collect a solid washed product. Washing may be performed by bringing the above amount of water into contact with the defatted plant seeds at once, or in multiple batches, or continuously. Good.
- the temperature at the time of contact is usually 5 to 45 ° C, preferably 25 to 35.
- the contact time is usually from 10 to 240 minutes, preferably from 15 to 60 minutes.
- the present invention is characterized in that a plant seed extract composition is obtained by extracting with an organic solvent from the defatted plant seed washed product obtained as described above.
- the organic solvent examples include, but are not limited to, lower alcohol, acetone, and a mixed solvent thereof.
- the organic solvent may contain water or may be anhydrous.
- the concentration of the organic solvent is usually 20 to 95 weight. /. Preferably, it is 50 to 90% by weight.
- the organic solvent is preferably a lower alcohol from the viewpoint of concentration, drying and food production of the extract after extraction.
- Examples of the lower alcohol include alcohols having 1 to 4 carbon atoms, and specific examples include, but are not limited to, methanol, ethanol, n-propanol, isopropanol, and n-ptanol.
- the lower alcohol is preferably ethanol from the viewpoint of food production.
- the ethanol is preferably hydrous ethanol or anhydrous ethanol containing 50% by weight or more of ethanol.
- the amount of the organic solvent to be used is usually 2 to 40 times the amount of the defatted plant seed as the raw material (organic solvent capacity / the weight of the defatted plant seed, the same applies hereinafter), and preferably 2 to 10 times the amount.
- the extraction temperature is usually from 20 to 75 ° C, preferably from 50 to 70 ° C.
- the extraction time is usually from 10 to 240 minutes, preferably from 60 to 120 minutes.
- the extract obtained by separating the solid content from the suspension by filtration or the like can be used as it is or, if necessary, concentrated and dried to obtain the plant seed extract composition of the present invention. Concentration and drying may be performed by concentrating and drying the extract as it is, or by adding a excipient (eg, lactose, sucrose, starch, cyclodextrin, etc.).
- a excipient eg, lactose, sucrose, starch, cyclodextrin, etc.
- the composition extracted with the above solvent is useful in its purity as the plant seed extract composition of the present invention, but may be further purified by a method known per se.
- the composition may contain a physiologically harmful solvent.
- a dried product or a product obtained by dissolving, suspending, or emulsifying the dried product in a physiologically acceptable solvent When present in a medium, use a dried product or a product obtained by dissolving, suspending, or emulsifying the dried product in a physiologically acceptable solvent.
- the form of the composition includes a liquid substance such as an aqueous liquid, a solid substance which is concentrated under reduced pressure and dried, and a solid substance such as a freeze-dried product.
- the plant seed extract composition of the present invention obtained by the above-mentioned method may be a serotonin derivative (for example, p-coumaronoreserotonin, phenoleroy reserotonin, p-kuma mouth iruse mouth toun glycoside and feruloylse mouth tonin glycoside, etc.) ) Is high in total and low in 2-hydroxyarctiin.
- the content means the content obtained when excipients are added, excluding the added excipients.
- safflower seed extract compositions have different powers depending on the purity of the composition and the like.
- P-Coumaroynoreserotonin, phenoleuroinoreserotonin, p-coumaroy Rose mouth tonin glycoside and feruloylcetone tonin glycoside are contained in a total amount of usually 10 to 70% by weight, preferably 20 to 50% by weight, based on the total amount of the plant seed extract composition.
- the content of, 2-hydroxyarctiin is usually at most 20% by weight, preferably at most 5% by weight, based on the total amount of the plant seed extract composition.
- the safflower seed extract composition includes p-coumaroy rotone, ferroy ⁇ / serotoun, ⁇ -coumaroylcetone tonin glycoside and
- the weight ratio of the total content of feruloylse mouth toun glycoside to the content of 2-hydroxyarctiin is usually 1: 0.05 to 0.2, preferably 1: 0.01 to 0.2.
- the present invention also relates to the total content of ⁇ -coumaroynoreserotonin, phenoleuroinoreserotonin, ⁇ -coumaroylcetone tonin glycoside and feruloylcetone tonin glycoside, the content of 2-hydroxyarctiin and Is a novel safflower seed extract composition having a weight ratio of 1: 0.05 to 0.2, preferably 1: 0.01 to 0.2.
- the novel safflower seed extract composition of the present invention can be suitably produced by the method of the present invention described above.
- the content of the serotoyun derivative is determined by using high performance liquid chromatography, using a water-containing acetonitrile as a developing solvent in a linear gradient with Shiseido's Capce 11 Pak C 18 column, using UV 29 O nm. The value measured by monitoring and comparing with a standard sample.
- the content of 2-hydroxyarctiin is determined by using a high-performance liquid chromatography with a Shiseido Capp 11 Pak C18 column and using a hydrous acetate as a developing solvent with UV 279 nm as a linear gradient. The value measured by monitoring and comparing with a standard sample.
- the plant seed extract composition of the present invention has a high content of a serotonin derivative, administration or ingestion of a serotonin derivative, or prophylactic treatment or prevention of a disease for which administration or ingestion is effective, For example, it can be used for prevention of arteriosclerosis.
- the plant seed extract composition of the present invention particularly the safflower seed extract composition, has a low content of 2-hydroxyarctiin, a diarrhea-inducing substance, and therefore has few side effects.
- the plant seed extract composition of the present invention is extremely useful as a pharmaceutical composition such as an arteriosclerosis preventive agent, a food product for preventing arteriosclerosis, and a feedstuff for preventing arteriosclerosis. .
- the plant seed extract composition of the present invention is useful for preventing arteriosclerosis and preventing diseases caused by arteriosclerosis, such as angina pectoris, myocardial infarction, intermittent claudication, and cerebral infarction. It is.
- the plant seed extract composition of the present invention can be used for animals other than humans and humans (for example, mammals other than humans (domestic animals such as pigs, pests, pomas, dogs, and cats), and birds (such as turkeys and chickens). It is useful to apply to poultry, etc.).
- mammals other than humans domestic animals such as pigs, pests, pomas, dogs, and cats
- birds such as turkeys and chickens. It is useful to apply to poultry, etc.).
- food in the present invention means food in general, but includes not only general foods including so-called health foods, but also specified health foods and nutritional foods specified in the Health Functional Food System of the Ministry of Health, Labor and Welfare. However, supplements are also included.
- the plant seed extract composition of the present invention itself can be used as a food, feed, or pharmaceutical composition.
- the plant seed extract composition of the present invention can be used for various foods, for example, for example, it can be used in general foods (including so-called health foods) such as dressings and mayonnaise.
- the plant seed extract composition of the present invention may be used together with excipients (eg, lactose, sucrose, starch, etc.), and, in some cases, flavors, pigments, etc., together with tablets, pills, granules, fine granules, powders, and pellets.
- the plant seed extract composition of the present invention can be applied to feed applications, and poultry and livestock can be ingested or administered by adding sorghum to ordinary feed.
- a pharmaceutical composition in the case of a pharmaceutical composition, it can be formulated together with a pharmaceutically acceptable carrier (including additives).
- pharmaceutically acceptable carriers as known to those skilled in the art, for example, excipients (eg, lactose, sucrose, starch, D-man-tol, etc.), binders (eg, cellulose, sucrose, dextrin, etc.) Hydroxypropylcellulose, polyvinylpyrrolidone, etc.), disintegrants (eg, starch, carboxymethylcellulose, etc.), lubricants (eg, magnesium stearate, etc.), surfactants (eg, sodium lauryl sulfate, etc.), Examples include, but are not limited to, solvents (eg, water, saline, soybean oil, etc.), preservatives (eg, p-hydroxybenzoate, etc.).
- the intake or dosage of the plant seed extract composition of the present invention varies depending on the purity of the composition, the age, weight, health condition, type of disease, etc. of the subject. It is preferable to take or take 1 O mg to 10 g, preferably 100 mg to 10 g per day, once to several times a day.
- the plant seed extract composition produced by the method of the present invention uses plant seeds conventionally used as edibles, particularly safflower seeds, which is a raw material of edible oil, and has a low content of diarrhea-inducing substances. The toxicity is extremely low, and there are few side effects.
- 0.1 kg of defatted safflower seeds (safflower meal) is placed in a container equipped with a stirrer, added with 0.5 L of water, stirred at a temperature of 30 ° C for 30 minutes, and then centrifuged at room temperature with a centrifugal filter (200 g). It was separated into a solid content and a washing solution. Washing by adding 0.5 L of water to the solid content was repeated four times.
- the safflower meal extract of each of the manufactured examples was analyzed according to the following method, and p-coumarone reserotonin (CS), phenololeno reserotonin (FS), and p-coumaroyl serotonin glycoside were analyzed.
- CS-Glc p-coumarone reserotonin
- FS-Glc feruloylserotone glycoside
- 2-hydroxyactiin were analyzed. The results are shown in Tables 1-3.
- safflower meal extract 5 mg was dissolved and dispersed in 50 ml of ethanol. This dispersion was used as an analysis sample.
- This analytical sample was subjected to high performance liquid chromatography under the following conditions to analyze serotonin derivatives.
- p-coumaroylcetone tonin and phenoleuroinoreserotonin used were those obtained by condensation of serotonin with trans-4-coumanoleic acid or trans-4-ferulic acid.
- the p-coumaroylce tonine glycoside and feruloylse tonine glycoside used were those obtained by the method described in Chemical and Pharmaceutical Bulletin 45 vol. 1910-1914 (1997).
- Rats (SD (IGS), female, 7 weeks old) were given a single oral administration (suspension in 0.5% carboxymethylcellulose) of safflower meal extract (compositions in Table 1 and Table 3). The presence or absence of diarrhea and loose stool up to 24 hours after administration was confirmed directly on a fecal dish.
- Table 4 shows the results. As is clear from Table 4, diarrhea was observed in all rats at 1,000 mg / kg in the rats to which the water-unwashed sample of Comparative Example 1 (Table 3 composition) was administered. In rats to which an extract sample (Table 1 composition) after washing with water of the present invention (Table 1 composition) was orally administered, there was no effect at 200 mg / kg, and diarrhea remained in 2/7 cases even at a high dose of 1,000 mg / kg. Improved laxative properties
- rapeseed meal, soybean meal, soybean germ meal, and soybean hulls were also prepared after oil extraction, and 1/10 of the extract was added with 1 ml of DMS0 and dissolved. It was used as a sample.
- PBS phosphate buffer
- Preparation of extracts of rapeseed meal and safflower meal was performed as follows. To 600 g of the rapeseed meal after oiling, 3000 ml of 90% by volume ethanol water was added, and the mixture was heated and stirred in a 60 ° C water bath for 3 hours and then filtered. The same operation was performed once for the solid content after filtration, and the obtained filtrates were combined and concentrated under reduced pressure to obtain a 500 ml concentrate. Water was added to the concentrated solution to make up to 1000 ml, the content was suspended, and then washed twice with 500 ml of n-hexane, and the washed aqueous layer was extracted twice with 500 ml of ethyl acetate. The ethyl acetate extract was dehydrated with anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to obtain 12.5 g of the extract.
- the safflower meal extract (SFM) used in this reference example was prepared according to the method described in reference example 2.
- SFM safflower meal extract
- the mice were sacrificed and sections of the aortic root were prepared, and lipid deposition sites (arteriosclerotic lesions) were stained with oil oil 0.
- Three sections were prepared for each individual, and image analysis (using WinROOF (Mitani Corporation)) was performed on the specimen in which the aortic valve was clearly seen, and the method of Rajendra et al. (J. Lipid Res., 36: ⁇ 2320- 2328, 1995) The product was measured.
- the obtained lesion area was analyzed for variance between each group, and when a significant difference was found, the average value between groups was compared by Scheffe test.
- the plant seed extract composition provided by the present invention is remarkably effective in preventing arteriosclerosis. Further, since the plant seed extract composition of the present invention is a naturally derived material, it is highly safe and has almost no side effects. Therefore, the food, feed, and pharmaceutical composition of the present invention are advantageous because they have no problem in use. Furthermore, the method of the present invention is effective for obtaining the plant seed extract composition of the present invention having a high content of the active ingredient and a low content of the diarrhea-inducing substance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Fodder In General (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002540849A CA2540849A1 (en) | 2003-10-10 | 2004-10-06 | Plant seed extract composition and process for producing the same |
JP2005514639A JP4720504B2 (ja) | 2003-10-10 | 2004-10-06 | 植物種子抽出組成物及びその製造方法 |
EP04792327A EP1679079A4 (en) | 2003-10-10 | 2004-10-06 | PLANT SEA EXTRACT COMPOSITION AND MANUFACTURING METHOD THEREFOR |
US11/400,188 US7767236B2 (en) | 2003-10-10 | 2006-04-10 | Plant seed extract composition and process for producing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-352829 | 2003-10-10 | ||
JP2003352829 | 2003-10-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/400,188 Continuation US7767236B2 (en) | 2003-10-10 | 2006-04-10 | Plant seed extract composition and process for producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005034975A1 true WO2005034975A1 (ja) | 2005-04-21 |
Family
ID=34431134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/015087 WO2005034975A1 (ja) | 2003-10-10 | 2004-10-06 | 植物種子抽出組成物及びその製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7767236B2 (ja) |
EP (1) | EP1679079A4 (ja) |
JP (1) | JP4720504B2 (ja) |
KR (1) | KR20060120096A (ja) |
CN (1) | CN100450497C (ja) |
CA (1) | CA2540849A1 (ja) |
WO (1) | WO2005034975A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007032551A1 (ja) * | 2005-09-14 | 2007-03-22 | Ajinomoto Co., Inc. | 血行動態改善剤 |
WO2007129743A1 (ja) * | 2006-05-10 | 2007-11-15 | Ajinomoto Co., Inc. | 抗炎症用組成物 |
JP2012097048A (ja) * | 2010-11-04 | 2012-05-24 | Kinki Univ | セロトニン誘導体を含むα−グルコシダーゼ阻害剤 |
JP2013537560A (ja) * | 2010-08-27 | 2013-10-03 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | 認知症の予防または治療用組成物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2021320B1 (en) * | 2018-07-17 | 2020-01-24 | Napiferyn Biotech Sp Z O O | Method for preparation protein-fibre concetrate from plant material |
CN109593540B (zh) * | 2018-12-26 | 2022-11-25 | 陕西煤业化工集团神木天元化工有限公司 | 煤焦油中酚类化合物的分离方法 |
CN110491266A (zh) * | 2019-08-26 | 2019-11-22 | 山东小巨人海洋科技有限公司 | 一种寻找有孔虫的实验课程 |
CN118084993A (zh) * | 2024-02-03 | 2024-05-28 | 新疆维吾尔自治区水产科学研究所 | 一种红花籽粕中2-羟基牛蒡子苷和罗汉松树脂苷的提取和检测方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH034607A (ja) | 1989-05-31 | 1991-01-10 | Kyocera Corp | 光検出増幅器 |
WO2003086437A1 (fr) * | 2002-04-12 | 2003-10-23 | Ajinomoto Co., Inc. | Composition destinee a prevenir l'arteriosclerose |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4072669A (en) * | 1977-03-07 | 1978-02-07 | The United States Of America As Represented By The Secretary Of Agriculture | Preparation of protein isolates from safflower seeds |
JPS5942000B2 (ja) * | 1978-04-03 | 1984-10-11 | 味の素株式会社 | 複素環フエノ−ル化合物aos |
JPH023495A (ja) * | 1988-06-13 | 1990-01-09 | Okuno Seiyaku Kogyo Kk | 抗酸化剤 |
US5714164A (en) * | 1991-02-28 | 1998-02-03 | Parfums Christian Dior | Method for treatment of allergic disorders and cosmetic compositions using cucurbitine |
JPH0739576A (ja) * | 1993-05-20 | 1995-02-10 | Okuno Chem Ind Co Ltd | 消臭剤 |
JP4111466B2 (ja) * | 1997-04-11 | 2008-07-02 | 竹本油脂株式会社 | セサミノールトリグルコシドの製造方法 |
KR100345825B1 (ko) * | 2000-01-22 | 2002-07-24 | 우리홍화인영농조합법인 | 홍화씨로부터 뼈 형성을 촉진하는 세로토닌, 리그난 및플라보노이드 성분의 추출방법 |
US7357951B2 (en) * | 2002-04-12 | 2008-04-15 | Ajinomoto Co., Inc. | Composition for preventing atherosclerosis |
US7396554B2 (en) * | 2002-08-16 | 2008-07-08 | Council Of Scientific & Industrial Research | Antioxidant sesame extract |
-
2004
- 2004-10-06 EP EP04792327A patent/EP1679079A4/en not_active Withdrawn
- 2004-10-06 CA CA002540849A patent/CA2540849A1/en not_active Abandoned
- 2004-10-06 CN CNB2004800295765A patent/CN100450497C/zh not_active Expired - Fee Related
- 2004-10-06 KR KR1020067009096A patent/KR20060120096A/ko not_active Application Discontinuation
- 2004-10-06 WO PCT/JP2004/015087 patent/WO2005034975A1/ja active Application Filing
- 2004-10-06 JP JP2005514639A patent/JP4720504B2/ja not_active Expired - Fee Related
-
2006
- 2006-04-10 US US11/400,188 patent/US7767236B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH034607A (ja) | 1989-05-31 | 1991-01-10 | Kyocera Corp | 光検出増幅器 |
WO2003086437A1 (fr) * | 2002-04-12 | 2003-10-23 | Ajinomoto Co., Inc. | Composition destinee a prevenir l'arteriosclerose |
Non-Patent Citations (8)
Title |
---|
HUI LI ZHANG ET AL.: "Antioxidative compounds isolated from Safflower (Carthamus tinctorius l.) oil cake", CHEM. PHARM. BULL., vol. 45, no. 12, 1997, pages 1910 - 1914, XP002988120 * |
JAE HI KIM ET AL.: "Lignan from Safflower seeds induces apoptosis in human polymyelocytic leukemia cells", NEURACEUTICALS & FOOD, vol. 8, 2 August 2003 (2003-08-02), pages 113 - 138, XP002988122 * |
KAWASHIMA S. ET AL.: "Serotonin derivative N-(p-coumaroyl)serotonin, inhibits the production TNF-alpha, IL-1alpha IL-1beta, and IL-6 by endotoxin-stimulated human blood monocytes", J. INTERFERON AND CYTOKINE RESEARCH, vol. 18, 1998, pages 423 - 428, XP002988121 * |
RAZIA TASNEEM ET AL.: "Effect of aqueous ethanol washing on the physicochemical and functional properties of Safflower (Carthamus tinctorius) seed protein", J. SCI. FOOD AGRIC., vol. 59, 1992, pages 237 - 244, XP002988124 * |
RHODA PALTER ET AL.: "A catharlic lignan glycoside isolated from carthamus tinctorus", PHYTOCHEMISTRY, vol. 11, no. 9, 1972, pages 2871 - 2874, XP002988123 * |
See also references of EP1679079A1 |
SUNG-HEE CHO ET AL.: "Effects of defatted sanflower seed extracts on plasma and liver lipid in ovariectomized female rats fed high cholesterol diets", FASEB J., vol. 15, no. 5, 2002, XP002988118 * |
ZHANG HUI LI ET AL.: "Yuryo shushi ni gan'yu sareru kosanka busshitsu no kenkyu - benibana aburakasu oyobi menjitsu no tansaku", SYMPOSIUM ON THE CHEMISTRY OF NATURAL PRODUCTS, SYMPOSIUM PAPERS, vol. 39, 1997, pages 559 - 564, XP002988119 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007032551A1 (ja) * | 2005-09-14 | 2007-03-22 | Ajinomoto Co., Inc. | 血行動態改善剤 |
US8080564B2 (en) | 2005-09-14 | 2011-12-20 | Ajinomoto Co., Inc. | Hemodynamics improving agent |
CN102764255A (zh) * | 2005-09-14 | 2012-11-07 | 味之素株式会社 | 血流动力学改善剂 |
JP2013028642A (ja) * | 2005-09-14 | 2013-02-07 | Ajinomoto Co Inc | 血行動態改善剤 |
JP5677717B2 (ja) * | 2005-09-14 | 2015-02-25 | 味の素株式会社 | 血行動態改善剤 |
JP2015155408A (ja) * | 2005-09-14 | 2015-08-27 | 味の素株式会社 | 血行動態改善剤 |
WO2007129743A1 (ja) * | 2006-05-10 | 2007-11-15 | Ajinomoto Co., Inc. | 抗炎症用組成物 |
US8309576B2 (en) | 2006-05-10 | 2012-11-13 | Ajinomoto Co., Inc. | Method of treating inflammatory bowel disease |
JP5141553B2 (ja) * | 2006-05-10 | 2013-02-13 | 味の素株式会社 | 抗炎症用組成物 |
JP2013035858A (ja) * | 2006-05-10 | 2013-02-21 | Ajinomoto Co Inc | 抗炎症用組成物 |
JP2013537560A (ja) * | 2010-08-27 | 2013-10-03 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | 認知症の予防または治療用組成物 |
JP2012097048A (ja) * | 2010-11-04 | 2012-05-24 | Kinki Univ | セロトニン誘導体を含むα−グルコシダーゼ阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
CN100450497C (zh) | 2009-01-14 |
US7767236B2 (en) | 2010-08-03 |
JP4720504B2 (ja) | 2011-07-13 |
JPWO2005034975A1 (ja) | 2006-12-21 |
EP1679079A1 (en) | 2006-07-12 |
EP1679079A4 (en) | 2009-12-30 |
CN1863542A (zh) | 2006-11-15 |
KR20060120096A (ko) | 2006-11-24 |
CA2540849A1 (en) | 2005-04-21 |
US20060257540A1 (en) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2234928C2 (ru) | Продукты каротиноидолипидный, протеинсодержащей фракций морского огурца и способы их применения | |
US6399105B1 (en) | Sea cucumber carotenoid lipid fraction products and methods of use | |
JP2010534235A (ja) | ヒドロキシチロソル含有オリーブ抽出物による栄養製品の栄養強化及びヒドロキシチロソルにより栄養強化された栄養製品 | |
US7767236B2 (en) | Plant seed extract composition and process for producing the same | |
JP4686173B2 (ja) | ポリフェノールおよび/またはビタミンcを含有するアセロラ処理物 | |
TWI610680B (zh) | 含有去鼠李糖洋丁香酚苷(Des Rhamnosyl Acteoside)之橄欖萃取物 | |
US6676978B1 (en) | Method and compositions for producing berry derived products | |
US6423365B1 (en) | Method and compositions producing cherry derived products | |
JP2009007346A (ja) | 糖尿病併発疾病予防剤 | |
JP2002029975A (ja) | フリーラジカル消去剤 | |
JP3977889B2 (ja) | 蕎麦殻抽出物を有効成分とする薬剤 | |
JP4720086B2 (ja) | 動脈硬化予防用組成物 | |
US20080299239A1 (en) | Inhibitor of Glucose Absorption and Method for Producing the Same | |
US7357951B2 (en) | Composition for preventing atherosclerosis | |
JP2011037829A (ja) | 平滑筋弛緩剤 | |
JP3980952B2 (ja) | 植物抽出エキスを含有する腸溶性の脂肪吸収抑制剤およびそれを含有する食品 | |
JP6806729B2 (ja) | 黒大豆種皮抽出物とヒハツ抽出物を必須成分として含有する、血清中一酸化窒素産生増強用、肝臓中抗酸化機能改善促進用および血清中中性脂肪量低下機能促進用の可食性組成物および血管内皮機能改善剤 | |
JP2007099671A (ja) | 抗酸化組成物 | |
JP2009132634A (ja) | 抗肥満剤 | |
JP2023069459A (ja) | サイクリックampホスホジエステラーゼ活性阻害剤 | |
JP2007039445A (ja) | プロスタサイクリン産生増加剤及び血流促進剤 | |
JP2011052028A (ja) | ポリフェノールおよび/またはビタミンcを含有するアセロラ処理物 | |
TW201143787A (en) | Method for isolating sesquiterpenoid lactone compounds from Tithonia diversifolia (Hemsl.) A. Gray, compositions and use thereof | |
WO2006022314A1 (ja) | コレステロール代謝制御剤、それを含有する飲食品、食品添加物及び医薬 | |
KR20090104373A (ko) | 건강 추출물 또는 이로부터 분리된 활성 성분을 포함하는소염, 국소적 부종 경감, 수술 또는 타박상으로부터의 회복촉진, 또는 심장 질환의 치료 또는 예방을 위한 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480029576.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514639 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2540849 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11400188 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004792327 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067009096 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004792327 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11400188 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067009096 Country of ref document: KR |